Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

GH Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults.

In English

Författare

  • David B Allen
  • Philippe Backeljauw
  • Martin Bidlingmaier
  • Beverly Biller
  • Margaret Boguszewski
  • Pia Burman
  • Gary Butler
  • K Chihara
  • Jens Sandahl Christiansen
  • Stefano Cianfarani
  • Peter E Clayton
  • David Clemmons
  • Pinchas Cohen
  • Feyza Darendeliler
  • Cheri Deal
  • David P Dunger
  • Eva Marie Erfurth
  • John Fuqua
  • Adda Grimberg
  • Morey Haymond
  • Claire Higham
  • Ken K Y Ho
  • Andrew R Hoffman
  • Anita Cs Hokken-Koelega
  • Gudmundur Johannsson
  • Anders Juul
  • John J Kopchick
  • Peter Lee
  • Michael Pollak
  • Sally Radovick
  • Leslie Robison
  • Ron Rosenfeld
  • Richard J Ross
  • Lars Savendahl
  • Paul Saenger
  • H Toft Sorensen
  • Kirstine Stochholm
  • Christian J Strasburger
  • Anthony Swerdlow
  • Michael O Thorner
Visa allt

Summary, in English

Recombinant human growth hormone (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety including; cancer risk, impact on glucose homeostasis and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk and the need for longterm surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

Publiceringsår

2016

Språk

Engelska

Sidor

1-9

Publikation/Tidskrift/Serie

European Journal of Endocrinology

Volym

174

Issue

2

Dokumenttyp

Artikel i tidskrift

Förlag

Society of the European Journal of Endocrinology

Ämne

  • Endocrinology and Diabetes

Status

Published

Forskningsgrupp

  • Translational Muscle Research

ISBN/ISSN/Övrigt

  • ISSN: 1479-683X